Unichem Laboratories zooms on getting approval for Apremilast Tablets

19 Feb 2021 Evaluate

Unichem Laboratories is currently trading at Rs. 321.40, up by 15.80 points or 5.17% from its previous closing of Rs. 305.60 on the BSE.

The scrip opened at Rs. 306.00 and has touched a high and low of Rs. 329.25 and Rs. 306.00 respectively. So far 19656 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 332.40 on 08-Feb-2021 and a 52 week low of Rs. 75.10 on 24-Mar-2020.

Last one week high and low of the scrip stood at Rs. 329.25 and Rs. 296.30 respectively. The current market cap of the company is Rs. 2258.97 crore.

The promoters holding in the company stood at 50.93%, while Institutions and Non-Institutions held 10.63% and 38.44% respectively.

Unichem Laboratories has received ANDA approval for its Apremilast Tablets, 10 mg, 20 mg and 30 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Amgen’s Otezla (apremilast) Tablets, 10 mg, 20 mg, and 30 mg. Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

Unichem Laboratories is an international, integrated, specialty pharmaceutical company.

Unichem Lab Share Price

565.00 9.55 (1.72%)
10-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1505.20
Dr. Reddys Lab 5922.45
Cipla 1339.45
Zydus Lifesciences 983.05
Lupin 1609.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.